구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | dendritic cell vaccine therapy (dendritic cell vaccine therapy) Life Research Technologies GmbH·Unspecified Adult Solid Tumor, Pro… 59 trials |
|---|---|
Overview Program | dendritic cell vaccine therapy |
Overview Company | Life Research Technologies GmbH |
Overview Modality | ANTIBODY |
Overview Target | Unspecified Adult Solid Tumor, Protocol |
Overview Indication | Unspecified Adult Solid Tumor, Protocol Specific |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | checkpoint-mediated protection, and lesion-supportive inflammatory remodeling |
MoA Biomarker | biomarker for stratifying breast cancer patients according to prognosis and likely treatment benefit |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable. We retrospectively evaluated the safety and efficacy of neoantigen peptid… |
Toxicology CRS | Reported |
Clinical Safety signal | Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable. We retrospectively evaluated the safety and efficacy of neoantigen peptid… |
Clinical Selected reported efficacy | ORR 0.15% |
Clinical Reported ORR | 0.15% |
Clinical Reported PFS | 9.5 |
Clinical Reported OS | 28 |
Clinical Result source | ClinicalTrials.gov NCT00323115 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00323115 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | dendritic cell vaccine therapy (dendritic cell vaccine therapy) Life Research Technologies GmbH·Unspecified Adult Solid Tumor, Pro… 59 trials |
|---|---|
Overview Program | dendritic cell vaccine therapy |
Overview Company | Life Research Technologies GmbH |
Overview Modality | ANTIBODY |
Overview Target | Unspecified Adult Solid Tumor, Protocol |
Overview Indication | Unspecified Adult Solid Tumor, Protocol Specific |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | checkpoint-mediated protection, and lesion-supportive inflammatory remodeling |
MoA Biomarker | biomarker for stratifying breast cancer patients according to prognosis and likely treatment benefit |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable. We retrospectively evaluated the safety and efficacy of neoantigen peptid… |
Toxicology CRS | Reported |
Clinical Safety signal | Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable. We retrospectively evaluated the safety and efficacy of neoantigen peptid… |
Clinical Selected reported efficacy | ORR 0.15% |
Clinical Reported ORR | 0.15% |
Clinical Reported PFS | 9.5 |
Clinical Reported OS | 28 |
Clinical Result source | ClinicalTrials.gov NCT00323115 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00323115 |
추천 비교
추천 비교